Europe Medical Foods for Inborn Errors of Metabolism Market - Industry Trends and Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION 59

• 1.1 OBJECTIVES OF THE STUDY 59
• 1.2 MARKET DEFINITION 59
• 1.3 OVERVIEW 59
• 1.4 CURRENCY AND PRICING 61
• 1.5 LIMITATIONS 61
• 1.6 MARKETS COVERED 61

2 MARKET SEGMENTATION 67

• 2.1 MARKETS COVERED 67
• 2.2 GEOGRAPHICAL SCOPE 68
• 2.3 YEARS CONSIDERED FOR THE STUDY 69
• 2.4 DBMR TRIPOD DATA VALIDATION MODEL 70
• 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 73
• 2.6 MULTIVARIATE MODELLING 74
• 2.7 PRODUCTS LIFELINE CURVE 74
• 2.8 DBMR MARKET POSITION GRID 75
• 2.9 SECONDARY SOURCES 77
• 2.10 ASSUMPTIONS 77

3 EXECUTIVE SUMMARY 78

4 PREMIUM INSIGHT 81

• 4.1 PESTEL ANALYSIS 82
• 4.2 PORTER'S FIVE FORCES MODEL 83
• 4.3 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET ANALYSIS 84
• 4.4 PATENT ANALYSIS 85

5 PIPELINE ANALYSIS 87

6 EPIDEMIOLOGY 88

7 INDUSTRY INSIGHTS 89

• 7.1 DEMOGRAPHIC TRENDS 89
• 7.2 KEY PRICING STRATEGIES 91
• 7.3 KEY PATIENT ENROLLMENT STRATEGIES 92

8 REGULATORY SCENARIO FOR MEDICAL FOOD 94

9 MARKET OVERVIEW 97

• 9.1 DRIVERS 99
  • 9.1.1 RISING INCIDENCES OF INBORN ERRORS OF METABOLISM (IEM) 99
  • 9.1.2 RISING PREFERENCE FOR DIETARY SUPPLEMENTS OVER ENZYME REPLACEMENT THERAPY (ERT) 100
  • 9.1.3 INCREASE IN THE NUMBER OF NEW-BORN SCREENING PROCEDURES 101
  • 9.1.4 INCREASING SPENDING ON MEDICAL FOOD PRODUCTS 102
• 9.2 RESTRAINTS 103
  • 9.2.1 HIGH COST OF MEDICAL FOODS 103
  • 9.2.2 STRINGENT REGULATIONS FOR MEDICAL FOODS 104
• 9.3 OPPORTUNITIES 105
  • 9.3.1 GOVERNMENT INITIATIVES AND PROGRAMS FOR CREATING AWARENESS ABOUT INBORN ERRORS OF METABOLISM 105
  • 9.3.2 INCREASING COLLABORATIONS AND PARTNERSHIPS IN THE MARKET 107
  • 9.3.3 EXPANSION OF MEDICAL FOODS IN EMERGING MARKETS 107
• 9.4 CHALLENGES 108
  • 9.4.1 POOR ACCESSIBILITY OF MEDICAL FOODS 108
  • 9.4.2 ALTERNATIVE TREATMENT APPROACHES FOR INBORN ERRORS OF METABOLISM 109

10 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS 110

• 10.1 OVERVIEW 111
• 10.2 AMINO ACID 114
  • 10.2.1 AMINO ACID MIXTURES 115
    • 10.2.1.1 PHENYLADE 116
      • 10.2.1.1.1 DRINK MIX 116
      • 10.2.1.1.2 GMP MIX-IN 116
      • 10.2.1.1.3 GMP READY 116
      • 10.2.1.1.4 OTHERS 116
    • 10.2.1.2 PERIFLEX 116
    • 10.2.1.3 LOPHLEX 117
    • 10.2.1.4 PHLEXY 117
    • 10.2.1.5 COOLER 117
    • 10.2.1.6 ANAMIX 117
    • 10.2.1.7 LYSINE-FREE, LOW TRYPTOPHAN 117
    • 10.2.1.8 GLUTARADE ESSENTIAL GA-1 117
    • 10.2.1.9 GLUTARADE GA-1 AMINO ACID BLEND 117
    • 10.2.1.10 GLYTACTIN WITH GMP 117
    • 10.2.1.11 ESSENTIAL AMINO ACID MIX 117
    • 10.2.1.12 LIQUIGEN 117
    • 10.2.1.13 MSUD GEL 118
    • 10.2.1.14 OTHERS 118
  • 10.2.2 SINGLE AMINO ACID 118
    • 10.2.2.1 L-ARGININE 118
    • 10.2.2.2 L-ISOLEUCINE 118
    • 10.2.2.3 L-TYROSINE 119
    • 10.2.2.4 L-LEUCINE 119
    • 10.2.2.5 GLYCINE 119
    • 10.2.2.6 L-ASPARTIC ACID 119
    • 10.2.2.7 L-CITRULLINE 119
    • 10.2.2.8 OTHERS 119
• 10.3 LOW PROTEIN FOOD 119
  • 10.3.1 LOW-PROTEIN BAKING MIXES AND FLOUR SUBSTITUTES, SUCH AS RICE FLOUR OR POTATO FLOUR 121
  • 10.3.2 LOW-PROTEIN ENERGY BARS AND SNACKS 121
  • 10.3.3 LOW-PROTEIN CEREALS AND BREAKFAST FOOD 121
  • 10.3.4 LOW-PROTEIN MILK SUBSTITUTES, SUCH AS RICE MILK OR ALMOND MILK 121
  • 10.3.5 LOW-PROTEIN BREAD, PASTA, AND OTHER GRAIN-BASED PRODUCTS 121
  • 10.3.6 OTHERS 121
• 10.4 GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON 121
  • 10.4.1 BY FLAVOUR 122
    • 10.4.1.1 VANILLA 122
    • 10.4.1.2 BERRY 122
    • 10.4.1.3 ORANGE 123
    • 10.4.1.4 PLAIN 123
    • 10.4.1.5 OTHERS 123
  • 10.4.2 BY USAGE 123
    • 10.4.2.1 READY TO DRINK 123
    • 10.4.2.2 NEED DILUTION/PREPARATION 123
• 10.5 LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON 124
  • 10.5.1 NO CALCIUM OR VITAMIN D 125
  • 10.5.2 LOW CALCIUM, NO VITAMIN D 125
  • 10.5.3 OTHERS 125
• 10.6 OTHERS 125

11 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES 127

• 11.1 OVERVIEW 128
• 11.2 PHENYLKETONURIA (PKU) 131
  • 11.2.1 PHENYLADE 132
  • 11.2.2 PERIFLEX 132
  • 11.2.3 LOPHLEX 132
  • 11.2.4 OTHERS 132
• 11.3 TYROSINEMIA TYPES I AND II 132
• 11.4 MAPLE SYRUP URINE DISEASE (MSUD) 133
  • 11.4.1 ANAMIX 134
  • 11.4.2 COOLER 134
  • 11.4.3 MSUD GEL 134
  • 11.4.4 AMINO ACID BLEND 134
  • 11.4.5 MAXMUM 134
  • 11.4.6 OTHERS 134
• 11.5 HOMOCYSTINURIA 135
• 11.6 GLUTARIC ACIDEMIA TYPE I 135
• 11.7 UREA CYCLE DISORDERS 136
  • 11.7.1 ORNITHINE TRANSCARBAMYLASE DEFICIENCY (OTC) 137
  • 11.7.2 CARBAMYL PHOSPHATE SYNTHETASE DEFICIENCY (CPS) 137
  • 11.7.3 CITRULLINAEMIA 137
  • 11.7.4 N-ACETYLGLUTAMATE SYNTHETASE DEFICIENCY (NAGS) 137
  • 11.7.5 ARGINASE DEFICIENCY (AG) 138
  • 11.7.6 ARGININOSUCCINIC ACIDURIA (ASA) 138
  • 11.7.7 OTHERS 138
• 11.8 METHYLMALONIC ACIDEMIA 138
• 11.9 ISOVALERIC ACIDEMIA 139
• 11.10 ORGANIC ACIDURIAS 140
• 11.11 RENAL DISEASE 140
• 11.12 PROPIONIC ACIDEMIA 141
• 11.13 DISORDERS OF LEUCINE METABOLISM 142
• 11.14 OTHERS 143

12 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP 144

• 12.1 OVERVIEW 145
• 12.2 INFANTS 148
• 12.3 WEANING 148
• 12.4 ADOLESCENT 149
• 12.5 ADULTS 150

13 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORMS 151

• 13.1 OVERVIEW 152
• 13.2 POWDER 155
• 13.3 LIQUID 155
• 13.4 TABLETS 156
• 13.5 GELS 157
• 13.6 OTHERS 158

14 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING 159

• 14.1 OVERVIEW 160
• 14.2 CAN 163
• 14.3 PACKETS 163
• 14.4 BOTTLE 164
• 14.5 JAR 165
• 14.6 OTHERS 165

15 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL 167

• 15.1 OVERVIEW 168
• 15.2 HOSPITAL PHARMACY 171
• 15.3 RETAIL PHARMACY 171
• 15.4 DRUG STORES 172
• 15.5 ONLINE PHARMACY 173
• 15.6 OTHERS 173

16 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION 175

• 16.1 EUROPE 176
  • 16.1.1 GERMANY 190
  • 16.1.2 FRANCE 199
  • 16.1.3 U.K. 208
  • 16.1.4 ITALY 217
  • 16.1.5 SPAIN 226
  • 16.1.6 SWITZERLAND 236
  • 16.1.7 NETHERLANDS 245
  • 16.1.8 BELGIUM 254
  • 16.1.9 DENMARK 263
  • 16.1.10 RUSSIA 272
  • 16.1.11 SWEDEN 280
  • 16.1.12 TURKEY 288
  • 16.1.13 POLAND 296
  • 16.1.14 FINLAND 304
  • 16.1.15 NORWAY 311
  • 16.1.16 REST OF EUROPE 319

17 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, COMPANY LANDSCAPE 320

• 17.1 COMPANY SHARE ANALYSIS: EUROPE 320

18 SWOT ANALYSIS 321

19 COMPANY PROFILE 322

• 19.1 ABBOTT 322
  • 19.1.1 COMPANY SNAPSHOT 322
  • 19.1.2 REVENUE ANALYSIS 322
  • 19.1.3 COMPANY SHARE ANALYSIS 323
  • 19.1.4 PRODUCT PORTFOLIO 323
  • 19.1.5 RECENT DEVELOPMENT 324
• 19.2 NESTLE HEALTH SCIENCE (A SUBSIDIARY OF NESTLE) 325
  • 19.2.1 COMPANY SNAPSHOT 325
  • 19.2.2 COMPANY SHARE ANALYSIS 325
  • 19.2.3 PRODUCT PORTFOLIO 326
  • 19.2.4 RECENT DEVELOPMENT 326
• 19.3 AJINOMOTO CAMBROOKE, INC. (A SUBSIDIARY OF AJINOMOTO CO., INC.) 327
  • 19.3.1 COMPANY SNAPSHOT 327
  • 19.3.2 COMPANY SHARE ANALYSIS 327
  • 19.3.3 PRODUCT PORTFOLIO 328
  • 19.3.4 RECENT DEVELOPMENTS 328
• 19.4 MEAD JOHNSON & COMPANY, LLC. (A SUBSIDIARY OF RECKITT BENCKISER GROUP PLC.) 329
  • 19.4.1 COMPANY SNAPSHOT 329
  • 19.4.2 COMPANY SHARE ANALYSIS 329
  • 19.4.3 PRODUCT PORTFOLIO 330
  • 19.4.4 RECENT DEVELOPMENT 330
• 19.5 NUTRICIA (A SUBSIDIARY OF DANONE) 331
  • 19.5.1 COMPANY SNAPSHOT 331
  • 19.5.2 COMPANY SHARE ANALYSIS 331
  • 19.5.3 PRODUCT PORTFOLIO 332
  • 19.5.4 RECENT DEVELOPMENT 333
• 19.6 APR 334
  • 19.6.1 COMPANY SNAPSHOT 334
  • 19.6.2 PRODUCT PORTFOLIO 334
  • 19.6.3 RECENT DEVELOPMENT 334
• 19.7 B.BRAUN SE 335
  • 19.7.1 COMPANY SNAPSHOT 335
  • 19.7.2 PRODUCT PORTFOLIO 335
  • 19.7.3 RECENT DEVELOPMENT 335
• 19.8 BAXTER 336
  • 19.8.1 COMPANY SNAPSHOT 336
  • 19.8.2 REVENUE ANALYSIS 336
  • 19.8.3 PRODUCT PORTFOLIO 337
  • 19.8.4 RECENT DEVELOPMENT 337
• 19.9 DR. SCHAR AG / SPA 338
  • 19.9.1 COMPANY SNAPSHOT 338
  • 19.9.2 PRODUCT PORTFOLIO 338
  • 19.9.3 RECENT DEVELOPMENT 339
• 19.10 EBM MEDICAL 340
  • 19.10.1 COMPANY SNAPSHOT 340
  • 19.10.2 PRODUCT PORTFOLIO 340
  • 19.10.3 RECENT DEVELOPMENT 340
• 19.11 ENER-G FOODS, INC. 341
  • 19.11.1 COMPANY SNAPSHOT 341
  • 19.11.2 PRODUCT PORTFOLIO 341
  • 19.11.3 RECENT DEVELOPMENT 341
• 19.12 FRESENIUS KABI AG (SUBSIDIARY OF FRESENIUS SE & CO. KGAA) 342
  • 19.12.1 COMPANY SNAPSHOT 342
  • 19.12.2 PRODUCT PORTFOLIO 342
  • 19.12.3 RECENT DEVELOPMENT 342
• 19.13 GALEN LIMITED 343
  • 19.13.1 COMPANY SNAPSHOT 343
  • 19.13.2 PRODUCT PORTFOLIO 343
  • 19.13.3 RECENT DEVELOPMENTS 343
• 19.14 HEXAGONNUTRITION LTD. 344
  • 19.14.1 COMPANY SNAPSHOT 344
  • 19.14.2 PRODUCT PORTFOLIO 344
  • 19.14.3 RECENT DEVELOPMENT 344
• 19.15 KATE FARMS 345
  • 19.15.1 COMPANY SNAPSHOT 345
  • 19.15.2 PRODUCT PORTFOLIO 345
  • 19.15.3 RECENT DEVELOPMENTS 346
• 19.16 MEIJI HOLDINGS CO., LTD. 347
  • 19.16.1 COMPANY SNAPSHOT 347
  • 19.16.2 REVENUE ANALYSIS 347
  • 19.16.3 PRODUCT PORTFOLIO 348
  • 19.16.4 RECENT DEVELOPMENT 348

• 19.17 ORPHARMA PTY LTD. 349
  • 19.17.1 COMPANY SNAPSHOT 349
  • 19.17.2 PRODUCT PORTFOLIO 349
  • 19.17.3 RECENT DEVELOPMENT 349
• 19.18 PIAM FARMACEUTICI S.P.A 350
  • 19.18.1 COMPANY SNAPSHOT 350
  • 19.18.2 PRODUCT PORTFOLIO 351
  • 19.18.3 RECENT DEVELOPMENT 351
• 19.19 PKU PERSPECTIVES 352
  • 19.19.1 COMPANY SNAPSHOT 352
  • 19.19.2 PRODUCT PORTFOLIO 352
  • 19.19.3 RECENT DEVELOPMENTS 352
• 19.20 PKU-MDMIL 353
  • 19.20.1 COMPANY SNAPSHOT 353
  • 19.20.2 PRODUCT PORTFOLIO 353
  • 19.20.3 RECENT DEVELOPMENT 353
• 19.21 PRIMUS PHARMACEUTICALS, INC. 354
  • 19.21.1 COMPANY SNAPSHOT 354
  • 19.21.2 PRODUCT PORTFOLIO 354
  • 19.21.3 RECENT DEVELOPMENT 354
• 19.22 PRISTINE ORGANICS PRIVATE LIMITED 355
  • 19.22.1 COMPANY SNAPSHOT 355
  • 19.22.2 PRODUCT PORTFOLIO 356
  • 19.22.3 RECENT DEVELOPMENT 356
• 19.23 PROMIN METABOLICS 357
  • 19.23.1 COMPANY SNAPSHOT 357
  • 19.23.2 PRODUCT PORTFOLIO 358
  • 19.23.3 RECENT DEVELOPMENT 358
• 19.24 SOLACE NUTRITION 359
  • 19.24.1 COMPANY SNAPSHOT 359
  • 19.24.2 PRODUCT PORTFOLIO 359
  • 19.24.3 RECENT DEVELOPMENT 360

20 QUESTIONNAIRE 361

21 RELATED REPORTS 365

LIST OF TABLES

• TABLE 1 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, PATENT ANALYSIS 58
• TABLE 2 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, PIPELINE ANALYSIS 60
• TABLE 3 COSTS OF MEDICAL FOODS USED IN INBORN ERRORS OF METABOLISM (IEMS) 64
• TABLE 4 THE MANUFACTURING OF MEDICAL FOOD MUST COMPLY WITH THE BELOW GIVEN FDA REQUIREMENT: 67
• TABLE 5 COSTS OF MEDICAL FOODS 76
• TABLE 6 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-20307 (USD MILLION) 86
• TABLE 7 EUROPE AMINO ACID IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 87
• TABLE 8 EUROPE AMINO ACID IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 87
• TABLE 9 EUROPE AMINO ACID MIXTURES IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 88
• TABLE 10 EUROPE PHENYLADE IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 89
• TABLE 11 EUROPE SINGLE AMINO ACIDS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 91
• TABLE 12 EUROPE LOW PROTEIN FOOD IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2018-2030 (USD MILLION) 93
• TABLE 13 EUROPE LOW PROTEIN FOOD IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 93
• TABLE 14 EUROPE GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 95
• TABLE 15 EUROPE GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FLAVOURS, 2021-2030 (USD MILLION) 95
• TABLE 16 EUROPE GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY USAGE, 2021-2030 (USD MILLION) 96
• TABLE 17 EUROPE LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 97
• TABLE 18 EUROPE LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 97
• TABLE 19 EUROPE OTHERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 99
• TABLE 20 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 103
• TABLE 21 EUROPE PHENYLKETONURIA (PKU) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 104
• TABLE 22 EUROPE PHENYLKETONURIA (PKU) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 104
• TABLE 23 EUROPE TYROSINEMIA TYPES I AND II IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 106
• TABLE 24 EUROPE MAPLE SYRUP URINE DISEASE (MSUD) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 106
• TABLE 25 EUROPE MAPLE SYRUP URINE DISEASE(MSUD) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2018-2030 (USD MILLION) 107
• TABLE 26 EUROPE HOMOCYSTINURIA IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 108
• TABLE 27 EUROPE GLUTARIC ACIDEMIA TYPE I IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 109
• TABLE 28 EUROPE UREA CYCLE DISORDERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 109
• TABLE 29 EUROPE UREA CYCLE DISORDERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 110
• TABLE 30 EUROPE METHYLMALONIC ACIDEMIA IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 111
• TABLE 31 EUROPE ISOVALERIC ACIDEMIA IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 112
• TABLE 32 EUROPE ORGANIC ACIDURIAS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 113
• TABLE 33 EUROPE RENAL DISEASE IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2018-2030 (USD MILLION) 114
• TABLE 34 EUROPE PROPIONIC ACIDEMIA IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 114
• TABLE 35 EUROPE DISORDERS OF LEUCINE METABOLISM IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 115
• TABLE 36 EUROPE OTHERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 116
• TABLE 37 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 120
• TABLE 38 EUROPE INFANTS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 121
• TABLE 39 EUROPE WEANING IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 122
• TABLE 40 EUROPE ADOLESCENT IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 122
• TABLE 41 EUROPE ADULTS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 123
• TABLE 42 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORMS, 2021-2030 (USD MILLION) 127
• TABLE 43 EUROPE POWDER IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 128
• TABLE 44 EUROPE LIQUID IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 129
• TABLE 45 EUROPE TABLETS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 129
• TABLE 46 EUROPE GELS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 130
• TABLE 47 EUROPE OTHERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 131
• TABLE 48 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING, 2021-2030 (USD MILLION) 135
• TABLE 49 EUROPE CAN IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 136
• TABLE 50 EUROPE PACKETS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 137
• TABLE 51 EUROPE BOTTLE IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 137
• TABLE 52 EUROPE JAR IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 138
• TABLE 53 EUROPE OTHERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 139
• TABLE 54 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 143
• TABLE 55 EUROPE HOSPITAL PHARMACY IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 144
• TABLE 56 EUROPE RETAIL PHARMACY IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 145
• TABLE 57 EUROPE DRUG STORES IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 145
• TABLE 58 EUROPE ONLINE PHARMACY IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 146
• TABLE 59 EUROPE OTHERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION, 2021-2030 (USD MILLION) 147
• TABLE 60 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 153
• TABLE 61 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 154
• TABLE 62 EUROPE AMINO ACID IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 154
• TABLE 63 EUROPE AMINO ACID MIXTURES IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 155
• TABLE 64 EUROPE PHENYLADE IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 156
• TABLE 65 EUROPE SINGLE AMINO ACIDS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 156
• TABLE 66 EUROPE LOW PROTEIN FOOD IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 157
• TABLE 67 EUROPE GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FLAVORS, 2021-2030 (USD MILLION) 157
• TABLE 68 EUROPE GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY USAGES, 2021-2030 (USD MILLION) 158
• TABLE 69 EUROPE LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 158
• TABLE 70 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 159
• TABLE 71 EUROPE PHENYLKETONURIA (PKU) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 159
• TABLE 72 EUROPE MAPLE SYRUP URINE DISEASE (MSUD) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 160
• TABLE 73 EUROPE UREA CYCLE DISORDERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 160
• TABLE 74 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 161
• TABLE 75 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORMS, 2021-2030 (USD MILLION) 161
• TABLE 76 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING, 2021-2030 (USD MILLION) 162
• TABLE 77 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 162
• TABLE 78 GERMANY MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 163
• TABLE 79 GERMANY AMINO ACID IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 163
• TABLE 80 GERMANY AMINO ACID MIXTURES IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 164
• TABLE 81 GERMANY PHENYLADE IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 165
• TABLE 82 GERMANY SINGLE AMINO ACIDS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 165
• TABLE 83 GERMANY LOW PROTEIN FOOD IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 166
• TABLE 84 GERMANY GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FLAVORS, 2021-2030 (USD MILLION) 166
• TABLE 85 GERMANY GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY USAGES, 2021-2030 (USD MILLION) 167
• TABLE 86 GERMANY LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 167
• TABLE 87 GERMANY MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 168
• TABLE 88 GERMANY PHENYLKETONURIA (PKU) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 168
• TABLE 89 GERMANY MAPLE SYRUP URINE DISEASE (MSUD) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 169
• TABLE 90 GERMANY UREA CYCLE DISORDERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 169
• TABLE 91 GERMANY MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 170
• TABLE 92 GERMANY MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORMS, 2021-2030 (USD MILLION) 170
• TABLE 93 GERMANY MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING, 2021-2030 (USD MILLION) 171
• TABLE 94 GERMANY MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 171
• TABLE 95 FRANCE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 172
• TABLE 96 FRANCE AMINO ACID IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 172
• TABLE 97 FRANCE AMINO ACID MIXTURES IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 173
• TABLE 98 FRANCE PHENYLADE IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 174
• TABLE 99 FRANCE SINGLE AMINO ACIDS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 174
• TABLE 100 FRANCE LOW PROTEIN FOOD IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 175
• TABLE 101 FRANCE GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FLAVORS, 2021-2030 (USD MILLION) 175
• TABLE 102 FRANCE GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY USAGES, 2021-2030 (USD MILLION) 176
• TABLE 103 FRANCE LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 176
• TABLE 104 FRANCE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 177
• TABLE 105 FRANCE PHENYLKETONURIA (PKU) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 177
• TABLE 106 FRANCE MAPLE SYRUP URINE DISEASE (MSUD) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 178
• TABLE 107 FRANCE UREA CYCLE DISORDERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 178
• TABLE 108 FRANCE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 179
• TABLE 109 FRANCE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORMS, 2021-2030 (USD MILLION) 179
• TABLE 110 FRANCE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING, 2021-2030 (USD MILLION) 180
• TABLE 111 FRANCE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 180
• TABLE 112 U.K. MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 181
• TABLE 113 U.K. AMINO ACID IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 181
• TABLE 114 U.K. AMINO ACID MIXTURES IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 182
• TABLE 115 U.K. PHENYLADE IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 183
• TABLE 116 U.K. SINGLE AMINO ACIDS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 183
• TABLE 117 U.K. LOW PROTEIN FOOD IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 184
• TABLE 118 U.K. GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FLAVORS, 2021-2030 (USD MILLION) 184
• TABLE 119 U.K. GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY USAGES, 2021-2030 (USD MILLION) 185
• TABLE 120 U.K. LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 185
• TABLE 121 U.K. MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 186
• TABLE 122 U.K. PHENYLKETONURIA (PKU) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 186
• TABLE 123 U.K. MAPLE SYRUP URINE DISEASE (MSUD) IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 187
• TABLE 124 U.K. UREA CYCLE DISORDERS IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES, 2021-2030 (USD MILLION) 187
• TABLE 125 U.K. MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 188
• TABLE 126 U.K. MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORMS, 2021-2030 (USD MILLION) 188
• TABLE 127 U.K. MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING, 2021-2030 (USD MILLION) 189
• TABLE 128 U.K. MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 189
• TABLE 129 ITALY MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 190
• TABLE 130 ITALY AMINO ACID IN MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS, 2021-2030 (USD MILLION) 190

LIST OF FIGURES

• FIGURE 1 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: SEGMENTATION 39
• FIGURE 2 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: DATA TRIANGULATION 42
• FIGURE 3 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: DROC ANALYSIS 43
• FIGURE 4 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 44
• FIGURE 5 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: COMPANY RESEARCH ANALYSIS 44
• FIGURE 6 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: INTERVIEW DEMOGRAPHICS 45
• FIGURE 7 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: DBMR MARKET POSITION GRID 47
• FIGURE 8 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: SEGMENTATION 52
• FIGURE 9 A RISE IN THE INCIDENCE OF INBORN ERRORS OF METABOLISM AND AN INCREASE IN THE NUMBER OF THE NEWBORN SCREENING PROCEDURES ARE EXPECTED TO DRIVE THE EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030 53
• FIGURE 10 THE AMINO ACID SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET IN 2023 AND 2030 53
• FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET 70
• FIGURE 12 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PRODUCTS, 2022 83
• FIGURE 13 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PRODUCTS, 2023-2030 (USD MILLION) 84
• FIGURE 14 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PRODUCTS, CAGR (2023-2030) 84
• FIGURE 15 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PRODUCTS, LIFELINE CURVE 85
• FIGURE 16 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY DISEASES, 2022 100
• FIGURE 17 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY DISEASES, 2023-2030 (USD MILLION) 101
• FIGURE 18 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY DISEASES, CAGR (2023-2030) 101
• FIGURE 19 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY DISEASES, LIFELINE CURVE 102
• FIGURE 20 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY AGE GROUP, 2022 117
• FIGURE 21 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 118
• FIGURE 22 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY AGE GROUP, CAGR (2023-2030) 118
• FIGURE 23 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY AGE GROUP, LIFELINE CURVE 119
• FIGURE 24 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY FORMS, 2022 124
• FIGURE 25 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY FORMS, 2023-2030 (USD MILLION) 125
• FIGURE 26 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY FORMS, CAGR (2023-2030) 125
• FIGURE 27 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY FORMS, LIFELINE CURVE 126
• FIGURE 28 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PACKAGING, 2022 132
• FIGURE 29 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PACKAGING, 2023-2030 (USD MILLION) 133
• FIGURE 30 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PACKAGING, CAGR (2023-2030) 133
• FIGURE 31 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PACKAGING, LIFELINE CURVE 134
• FIGURE 32 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY DISTRIBUTION CHANNEL, 2022 140
• FIGURE 33 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 141
• FIGURE 34 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 141
• FIGURE 35 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 142
• FIGURE 36 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: SNAPSHOT (2022) 149

• FIGURE 37 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2022) 150
• FIGURE 38 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2023 & 2030) 150
• FIGURE 39 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY COUNTRY (2022 & 2030) 151
• FIGURE 40 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: BY PRODUCTS (2023-2030) 151
• FIGURE 41 EUROPE MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET: COMPANY SHARE 2022 (%) 292